Sarvear Pharmaceuticals UA

Selaqui, Dehradun, Uttarakhand

• Well tolerated with potential advantages activity against gram-negative pathogen
• Effective and well-tolerated antibiotic for the treatment of bacterial meningitis
• Higher rate of clinical success against primary or secondary lower respiratory tract infections
• Suitable choice for initial empirical antibiotic therapy for febrile episodes in neutropenic cancer patients
• Empirical monotherapy of serious bacterial infection in ICU patients

Indications : 

• Lower RTI 
• Septicaemia 
• Intra abdominal infections 
• Nosocomial Infections 
• Meningitis 
• Febrile Neutropenia 
• Gynaecological Infections

A Unique Monocyclic Beta-lactam With Beta-lactamase Stability

• Highly selective against Gram-negative aerobic bacteria
• Low MIC cidal action (less than or equal to 1.6 mg/L)
• Potent against pseudomonal infections
• Choicest alternative to aminoglycoside / 3rd generation cephalosporin resistant cases
• Safe in compromised kidney function scenario
• Urinary Tract Infections (complicated & uncomplicated), including pyelonephritis and cystitis
• Lower Respiratory Tract Infections, including endometritis and pelvic cellulitis ig TID-98% cure'
• Intra-abdominal infections, including peritonitis (95% microbiological curer)
• Skin and Skin-Structure Infections, including those associated with postoperative wounds, ulcers, and burns
• Bone & Joint Infections

Indications :

• Lower Respiratory Tract Infections
• Skin and Skin Structure Infections
• Urinary Tract Infections
• Pelvic Inflammatory Disease
• Bacterial Septicemia
• Bone & Joint Infections
• Intra-Abdominal Infections
• Central Nervous System Infections

• Wide spectrum action against aerobes & anaerobes
• More active than ceftazidime Wide spectrum of action including gram +ve & gram-ye coverage
• Cilastatin diminishes adverse reaction associated with imipenem administration

Dosage :

• Adults : In terms of Impenem , 1.2 g Daily in Divided Doses every 6-8 Irs given Via I.V. infusion
• Children : 3WS 15-25 mg/Kg Every 6 Hrs by IV Infusion Surgical Prophylaxis In Terms of Impenem 19 given on induction of anaesthesia followed by 1g 3 Hrs Later

Indications :

• Infections In Dialysis Patients 
• UT Infections 
• LRT Infections 
• Endocarditis 
• Gynaecological Infection 
• Diabetic Foot Infection 
• Intra Abdominal Infection 
• Bone & Joint Infections 
• Skin & Skin Structure Infection 
• Nosocomial Infections

• Appendicitis 
• Peritonitis 
• U.T.I. . 
• Skin & Soft Tissue Infections 
• Lower Respiratory Tract Infections 
• Infection In Neutropenic Patients
• Intra Abdominal Infections
• Pneumonia / Ventilator Associated Pneumonia / Hospital Acquired Pneumonia

The Active Therapy For Sure Eradication.That Saves Life

Ensures : 

• Vast Spectrum of Activity
  • Effective Against Pseudomonas, Klebsiella, Mixed, Aerobic - Anaerobic Infections 

• Potent synergism against beta-lactamase producing piperacillin resistant strains
  • Tazobactam enhances & extends antibiotic spectrum of Piperacillin without influencing Piperacillin's independent potency Pharmacokinetically matched combination with no adverse drug interaction 

• Potent for all mild, moderate & severe infections

The Combined Attack of Two Synergistic Antibacterials in Management of Severe & Resistant Infections  

• Synergistic combination for enhanced bactericidal action  
• Checks resistance against beta-lactamase & enhances spectrum of action  
• Highly effective against gram +ve, gram -ve bacteria & anaerobes  
• Achieves high conc. in CSF & tissue fluids  
• Offers deep tissue penetration for enhanced efficacy  
• Ensures safe & well tolerability profile.

Ceftroaxone :

• Active against aerobic gram +ve & gram -ve micro-organism & many anaerobic micro-organism  
• Achieves excellent tissue and fluid penetration
• Maintains longer half life among all cephalosporins allowing for once daily dosing

Sulbactam :

• Inactivates enzymes that destroy penicillins & cephalosporins by lactamase resistant structure
• Exhibits bactericidal activity against - Staphylococci, Haemophilus influenzae, Moraxella catarrhalis and Neisseria spp. Potentiates activity of lactamase sensitive ceftiaxone & increases its spectrum

Indicated in :

• Nosocomial infections &
• Surgical prophylaxis  
• Meningitis  
• Skin & soft tissue infections  
• STD  
• UTI  
• Chronic suppurative bacterial otitis media  
• Cholecystifis  Osteomyelitis  
• Infections in dialysis unit

Fights All Resistant Infections :

• Pharmacokinetic of this drug is not affected by presence of hepatic dysfunction
• Exhibits 92% efficacy as compared to 88% with Amoxy -Clavulanate combination
• Specifically used in febrile neutropenic patients with haematological malignancies & burns

Indications :

• Febrile neutropenic patients
• Bacterial arthritis
• Pseudomonas meningitis
• Immuocompromised Infections
• Skin, Soft tissue & bone Infections
• Septicaemia

• Resistant To Most Beta-lactamases
• Active Against Wide Range Of Gram + Ve & Gram -ve Organism
• Attains High Concentration In C.S.F. So Useful In Meningitis Caused By H. Influenza, Meningococci & Pheumococci

Ensures Outstanding Performance In :

• R.T.I.
• Genito U.T.I.
• Skin & Soft Tissue Infections
• Cervicitis
• Meningitis
• Surgical Prophylaxis
• Acute Otitis Media/Sinusitis
• Septic Arthritis
• Bone & Joint Infections
• Intra Abdominal Sepsis

• With high degree of stability in the presence of beta ladamases (both penicillinase and cephalosporinase) of gram +ve and grange baderia.
• Achieves excellent tissue and body fluid penetration
• Allows once daily dosing

The distinguishing feature of this cephalosporin is its longer duration of action (ti 2 8 his) permitting once or at the most twice daily dosing. In

• Meningitis
• Bacterial Septicemia
• Typhoid
• Pre ft Post Operative Infections
• Nosocomial Infections

Guarantees Effectiveness, Safety, Maintenance & 'Nil' Microbial Resistance

• Offers better success rate in comparison to ceftriaxone Et combination
• Promises synergistic action
• Ensures effective and safe treatment option
• Provides broader anti-bacterial coverage
  • Cefoperazone + Sulbactam is a promising combination for the treatment of infections due to certain cefoperazone resistant gram -ye bacilli ; e.g. P. aeruginosa, E. coli, N. gonorrhoea.*